PEB applies for ASX dual foreign exempt listing

Company Announcement
30 August 2021



PEB APPLIES FOR AUSTRALIAN STOCK EXCHANGE (ASX) DUAL FOREIGN EXEMPT LISTING

Cancer diagnostics business, Pacific Edge Limited (NZX: PEB) will lodge an application today with the Australian
Stock Exchange (ASX) to dual list as a Foreign Exempt Entity. Subject to the ASX accepting the application, PEB
expects to be dual-listed on the ASX by the end of September 2021.

Pacific Edge intends to maintain its primary listing on New Zealand Stock Exchange (NZX).

The Board believes that a dual listing on the ASX is a logical progression for the company and a way of accessing a
broader pool of institutional and retail investors who wish to share in PEB’s success. Increasing the liquidity of our
shares and widening our investor base have been consistent strategic objectives of the company.

The ASX has given its approval in principle for this application.

Chairman of Pacific Edge, Chris Gallaher, said: “We remain committed to our loyal New Zealand shareholder base,
and our intention is to remain a New Zealand domiciled business. We are now seeing the value of our long-term
strategy, with accelerating revenue growth as adoption of our Cxbladder products and test volumes grows. The
Board believes that listing on the ASX is a way, over time, of accessing a broader pool of specialist international
healthcare, institutional and retail investors, whilst providing a stronger share trading environment with greater
liquidity and the potential for ASX index inclusion, for the benefit of all shareholders.”

Pacific Edge is included in the S&P NZX50 and has a market cap of more than NZ$ 900 million (as at 28 August 2021).


ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz


OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

Company Announcement
30 August 2021


ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.